Celltrion’s Remicade Biosimilar Gets Adcomm Backing for 6 Indications

An FDA advisory committee gave South Korea’s Celltrion’s biosimilar candidate for Remicade a strong show of support Feb. 9, backing its approval for six indications.
Source: International Pharmaceutical Regulatory Monitor